Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes
Requires a prescription from a doctor or prescriber
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
16 branded products available
Part of the Fluarix brand family (generic: Influenza vaccine)
MHRA licensed products
View all licensed products for Influenza vaccine on the MHRA register
Influenza Tetra MYL vaccine suspension for injection 0.5ml pre-filled syringes
Cell-based quadrivalent influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes
Flucelvax Tetra vaccine suspension for injection 0.5ml pre-filled syringes
Fluvirin vaccine suspension for injection 0.5ml pre-filled syringes
Novartis Vaccines and Diagnostics Ltd
Imuvac vaccine suspension for injection 0.5ml pre-filled syringes
Influenza MYL vaccine suspension for injection 0.5ml pre-filled syringes
Influvac Desu vaccine suspension for injection 0.5ml pre-filled syringes
Abbott Healthcare Products Ltd
Influvac sub-unit Tetra vaccine suspension for injection 0.5ml pre-filled syringes
Influvac Sub-unit vaccine suspension for injection 0.5ml pre-filled syringes
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Flu vaccination: increasing uptake (QS190)
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Flu vaccination: increasing uptake (NG103)
Antenatal care (QS22)
Vaccine uptake in under 19s (QS145)
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Vaccine uptake in the general population (NG218)
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
Vitamin D: supplement use in specific population groups (PH56)
Pneumonia: diagnosis and management (NG250)
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 42 · Randomised trials: 8 · 1989–2026
Showing the 50 most relevant studies, sorted by most relevant.
Philipp Schmid, Dorothee Rauber, Cornelia Betsch, et al.
PLoS ONE, 2017
- Health Knowledge, Attitudes, Practice
- Health Personnel
- Influenza, Human
Edward A. Belongia, Melissa Simpson, Jennifer P. King, et al.
The Lancet Infectious Diseases, 2016
- Sentinel Surveillance
- Vaccine Potency
- Influenza, Human
A. Domnich, L. Arata, D. Amicizia, et al.
Vaccine, 2017
Andrea C. Tricco, Ayman Chit, Charlene Soobiah, et al.
BMC Medicine, 2013
- Influenza, Human
- Influenza Vaccines
- Species Specificity
Michael T. Osterholm, Nicholas S. Kelley, Alfred Sommer, et al.
The Lancet Infectious Diseases, 2011
- Influenza, Human
- Influenza Vaccines
Tom Jefferson, Daniela Rivetti, Alessandro Rivetti, et al.
The Lancet, 2005
- Influenza Vaccines
- Influenza, Human
- Drug Resistance, Viral
Kumanan Wilson, Nguyen, Holdt Henningsen, et al.
Infection and Drug Resistance, 2011
Tom Jefferson, Stephanie Smith, Vittorio Demicheli, et al.
The Lancet, 2005
- Influenza Vaccines
- Influenza, Human
- Vaccines, Attenuated
K. Wilkinson, Yichun Wei, Andrea Szwajcer, et al.
Vaccine, 2017
P. Groß, A. Hermogenes, H. Sacks, et al.
Annals of Internal Medicine, 1995
- Influenza Vaccines
- Age Factors
- Chronic Disease
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q1353540), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.